SEO URLwww.firestrike.ai/deals/stratadx-fulgent-genetics-acquisition-2026
acquisitionAnnounced · Jan 12, 2026lab testing and pharmaceuticalsSource · CredibleArticle · Factual
Fulgent Genetics acquires StrataDx
David Najork · Founding Software Engineer
Announced · Updated · 1 min read
Deal value
$56M
Target
StrataDx
Lexington, Massachusetts
Acquirer
Fulgent Genetics
Full Acquisition
Status
Pending
Fulgent Genetics agreed to acquire StrataDx. Reported deal value: $56M. Status: Pending. Sector: lab testing and pharmaceuticals. Target headquarters context: Lexington, Massachusetts, United States.
This page summarizes publicly available information about the transaction as of 2026-01-12. Figures and status may change as filings and press coverage update.
El Monte -based lab testing and pharmaceutical company Fulgent Genetics Inc. last month simultaneously announced a pair of lab oratory acquisitions for a combined total of nearly $56 million
Deal timeline
Announced
Jan 12, 2026 · labusinessjournal.com
Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.
Sector context
This transaction is classified in lab testing and pharmaceuticals with a reported deal value of $56M. Figures and status may change as sources update.
Sources: labusinessjournal.com · Primary article · FireStrike proprietary index